|Mr. Stanley Charles Erck||Pres, CEO & Director||N/A||N/A||1948|
|Mr. John Joseph Trizzino||Sr. VP, Chief Bus. Officer, CFO & Treasurer||N/A||N/A||1960|
|Mr. John A. Herrmann III||Sr. VP, Gen. Counsel & Corp. Sec.||488.32k||N/A||1966|
|Dr. Gregory M. Glenn||Pres of R&D||N/A||N/A||1954|
|Ms. Jill Hoyt||VP of HR & Admin.||N/A||N/A||N/A|
Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc.’s ISS Governance QualityScore as of November 1, 2018 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 7.